Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 520

1.

High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia.

Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC.

Biol Psychiatry. 2004 Jan 15;55(2):165-71.

PMID:
14732596
[PubMed - indexed for MEDLINE]
2.

D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia.

Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G, Catinari S, Ermilov M.

Biol Psychiatry. 2005 Mar 15;57(6):577-85.

PMID:
15780844
[PubMed - indexed for MEDLINE]
3.

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.

Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M.

Arch Gen Psychiatry. 1999 Jan;56(1):29-36.

PMID:
9892253
[PubMed - indexed for MEDLINE]
4.

Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia.

Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, Javitt DC.

Am J Psychiatry. 2002 Mar;159(3):480-2.

PMID:
11870017
[PubMed - indexed for MEDLINE]
5.

Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.

Kinon BJ, Basson BR, Gilmore JA, Malcolm S, Stauffer VL.

J Clin Psychiatry. 2000 Nov;61(11):833-40.

PMID:
11105736
[PubMed - indexed for MEDLINE]
6.

Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.

Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, Chakos M, McEvoy JP.

J Clin Psychiatry. 2002 Oct;63(10):931-5.

PMID:
12416603
[PubMed - indexed for MEDLINE]
7.

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.

Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA.

Am J Psychiatry. 2003 Feb;160(2):290-6.

PMID:
12562575
[PubMed - indexed for MEDLINE]
8.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
[PubMed - indexed for MEDLINE]
9.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
[PubMed - indexed for MEDLINE]
10.

Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.

Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE.

Arch Gen Psychiatry. 2005 Nov;62(11):1196-204.

PMID:
16275807
[PubMed - indexed for MEDLINE]
11.

The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.

David SR, Taylor CC, Kinon BJ, Breier A.

Clin Ther. 2000 Sep;22(9):1085-96.

PMID:
11048906
[PubMed - indexed for MEDLINE]
12.

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.

Tsai G, Lane HY, Yang P, Chong MY, Lange N.

Biol Psychiatry. 2004 Mar 1;55(5):452-6.

PMID:
15023571
[PubMed - indexed for MEDLINE]
13.

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA.

Am J Psychiatry. 2002 Feb;159(2):255-62. Erratum in: Am J Psychiatry 2002 Dec;159(12):2132.

PMID:
11823268
[PubMed - indexed for MEDLINE]
14.

Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.

Feldman PD, Kaiser CJ, Kennedy JS, Sutton VK, Tran PV, Tollefson GD, Zhang F, Breier A.

J Clin Psychiatry. 2003 Sep;64(9):998-1004.

PMID:
14628974
[PubMed - indexed for MEDLINE]
15.

Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.

Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M.

J Clin Psychiatry. 2004 Apr;65(4):551-6.

PMID:
15119920
[PubMed - indexed for MEDLINE]
16.

Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.

Weiden PJ, Simpson GM, Potkin SG, O'Sullivan RL.

J Clin Psychiatry. 2003 May;64(5):580-8.

PMID:
12755663
[PubMed - indexed for MEDLINE]
17.

Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study.

Cuesta MJ, Peralta V, Zarzuela A.

Schizophr Res. 2001 Mar 1;48(1):17-28. Review.

PMID:
11278151
[PubMed - indexed for MEDLINE]
18.

Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.

Edgell ET, Andersen SW, Johnstone BM, Dulisse B, Revicki D, Breier A.

Pharmacoeconomics. 2000 Dec;18(6):567-79.

PMID:
11227395
[PubMed - indexed for MEDLINE]
19.

Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia.

Kores Plesnicar B, Zalar B, Tomori M, Krajnc I.

Wien Klin Wochenschr. 2003 Jan 31;115(1-2):58-62.

PMID:
12658913
[PubMed - indexed for MEDLINE]
20.

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.

Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper TB, Horowitz TL, Lieberman JA.

Am J Psychiatry. 2002 Jun;159(6):1018-28.

PMID:
12042192
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk